PharmaNet Development Group Inc
Industrials · Services-Commercial Physical & Biological Research · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annualNo structured XBRL financials available (common for pre-2009 filers, foreign issuers, or companies that never reported as a US public company).
Signs
● 1 severe● 0 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-K/Amissed a reporting deadline ↗Mar 17, 2009
- NT 10-Kmissed a reporting deadline ↗Mar 17, 2009
- NT 10-Kmissed a reporting deadline ↗Mar 17, 2008
- NT 10-Kmissed a reporting deadline ↗Mar 16, 2007
- NT 10-Qmissed a reporting deadline ↗Aug 9, 2006
- NT 10-Qmissed a reporting deadline ↗May 10, 2006
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Olivier David MDirector | Mar 20, 2009 | U | 14,998 | $5.00 |
| Sheldrick Robin CashenOfficer — Senior VP, Human Resources | Mar 20, 2009 | U | 16,612 | $5.00 |
| Wold Olsen PerDirector | Mar 20, 2009 | U | 19,998 | $5.00 |
| Elias Lewis RDirector | Mar 20, 2009 | U | 20,424 | $5.00 |
| Mcmullen Jeffrey POfficer — Pres., CEO and Dir. | Mar 20, 2009 | U | 143,651 | $5.00 |
| Di Ianni MarkOfficer — EVP | Mar 20, 2009 | U | 19,315 | $5.00 |
| Classon Rolf ADirector | Mar 20, 2009 | U | 16,502 | $5.00 |
| Tombros Peter GDirector | Mar 20, 2009 | U | 21,377 | $5.00 |
| Golieb ArnoldDirector | Mar 20, 2009 | U | 25,971 | $5.00 |
| Newman Thomas JosephOfficer — EVP | Mar 20, 2009 | U | 54,463 | $5.00 |
| Hamill John POfficer — EVP and CFO | Mar 20, 2009 | U | 45,396 | $5.00 |
| Olivier David MDirector | Jun 4, 2008 | Grant | 7,654 | $16.33 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Director / officer change · Amended charter or bylawsApr 2, 2009
- Debt acceleration / triggering event · Change in control · Director / officer change · Other material eventMar 25, 2009
- Other material eventMar 17, 2009
- Results of operationsFeb 26, 2009
- Other material eventFeb 11, 2009
- Entered a material agreement · Modified shareholder rightsFeb 3, 2009
- Other material eventDec 19, 2008
- Director / officer changeDec 18, 2008
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/APHARMANET DEVELOPMENT GROUP 13GFeb 12, 2010
- NO ACTAUTO-GENERATED PAPER DOCUMENTMay 8, 2009
- NO ACTAUTO-GENERATED PAPER DOCUMENTMay 8, 2009
- NO ACTAUTO-GENERATED PAPER DOCUMENTMay 8, 2009
- 15-12BFORM 15 TBDMay 8, 2009
- SC 13G/AApr 9, 2009
- 8-KFORM 8-KApr 2, 2009
- EFFECTApr 1, 2009
- EFFECTApr 1, 2009
- EFFECTApr 1, 2009
- EFFECTApr 1, 2009
- EFFECTApr 1, 2009
- 25-NSEMar 31, 2009
- POS AMPOST-EFFECTIVE AMENDMENT NO. 2Mar 31, 2009
- POS AMPOST-EFFECTIVE AMEND. NO 4 TO FORM S-3Mar 31, 2009
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.